Redeye comments on BioInvent’s Q2 report 2025. New positive results with BI-1206 in solid tumours and Non-Hodgkin lymphoma and with BI-1808 in T-cell lymphoma were presented. A pause of BI-1607 and BI-1910 was announced yesterday as the company focuses on late- to mid-stage development of BI-1206 and BI-1808.
LÄS MER
